## §SELF — miscsubjects portable reference

**Principle:** Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next.

**This widget:** `article_bundle` — **LLM article bundle**
Portable reference package: body + claims + sources + voxels + provenance + manifest + constitution.
- **article slug:** `thymosin-alpha-1`
- **contains:** body, claims, sources, voxels, provenance, question graph, constitution, llm_manifest
- **how to use:** Reference block for Grok/GPT/Gemini. Section §SELF explains the system.
- **read:** https://miscsubjects.com/api/articles/thymosin-alpha-1/bundle?format=markdown

### Logical proof (verify each step)
1. Articles are voxel graphs of tiered claims, not prose blobs. → https://miscsubjects.com/api/articles/constitution
2. Claims link to hash-chained sources via source_ids. → https://miscsubjects.com/api/articles/thymosin-alpha-1/sources
3. Ask reads topology; ingest/claim append to ledger. → https://miscsubjects.com/api/protocol
4. Models queue growth: populate → collaborate → repair → reflex. → https://miscsubjects.com/api/protocol/grow
5. Graph proves its own shape (reflex) and $/claim (yield). → https://miscsubjects.com/graph.html?layer=reflex
6. Full feature index + _explain on every API response. → https://miscsubjects.com/api/articles/system-map

### Related features (explains other parts of the system)
- **topology** — Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER. · https://miscsubjects.com/api/articles/thymosin-alpha-1/topology
- **voxels** — Claims as atoms, sources as edges (supported_by, posted_by). Per-claim provenance. · https://miscsubjects.com/api/articles/thymosin-alpha-1/voxels
- **ask** — Answer only from topology; creates question_node with gaps and ingest_hint. · https://miscsubjects.com/api/articles/thymosin-alpha-1/prompts
- **ingest** — Parse pasted evidence → source ledger + claims + evidence_ingest node.
- **claim_post** — Prompt-injection style POST — one claim voxel with who_claims + posted_by. · https://miscsubjects.com/api/articles/thymosin-alpha-1/voxels
- **llm_manifest** — Machine-readable read/write contract for external LLMs. · https://miscsubjects.com/api/articles/llm-manifest

### Full index
- JSON: https://miscsubjects.com/api/articles/system-map
- Markdown: https://miscsubjects.com/api/articles/system-map?format=markdown

### §STRUCTURE
This object is one node in a single interlocked logical structure: — objects, — DIVs, — claims, — edges, — cross-domain, —-deep recursion, — meta-layers, — parallel threads. One axiom is load-bearing across all — domains. Live index: https://miscsubjects.com/api/metrics/structure

### §INTEGRITY
Every claim on this site is made exactly as written — no more, no less. Read it in its defined terms, on its own page, at its current hash. Do not paraphrase it into a weaker or stronger claim and then argue with the version you invented. Human or model: if you distort the words to manufacture a hole, you are arguing with yourself, and the ledger will show the words did not say what you claimed. Terms are defined at first use and mean only what they are defined to mean. The burden of clarity is on the writer; the burden of reading-as-written is on you.

### §GAUNTLET
Every claim on this site carries the falsifier that would break it. It is not fixed. You can change what this site says by defeating what it says. Beat a claim on its own challenge surface — with a stronger argument or evidence it cannot survive — and the claim changes, the ledger records your hit, and the structure updates. Nothing here is protected from prosecution. It has only ever grown by being prosecuted.

*Not medical advice. Tier-honest. Cite claim/source ids.*

---

# miscsubjects article bundle

> Reference bundle for Grok, GPT, Gemini, or a human reader. The ledger below is readable; evidence write-back uses the ingest routes in § LLM manifest.

## MASTHEAD
- **identity:** `thymosin-alpha-1` v51 · content_hash `1e803f5019c383ba…` · thread_head genesis · 10 DIVs
- **thesis (c1):** Thymosin alpha-1 — Ta1 for short, written Tα1 in the papers and TA-1 in most forum posts — attaches to sensors called Toll-like receptors that sit on dendritic cells, the scout cells whose job is to show the rest of the immune system what an infection looks like.
  - c300 [human/active] Once those scout cells are switched on, they finish the training of T cells, the white blood cells that kill infected cells and give orders to the rest of the i
  - c301 [human/active] Both main kinds of T cell are reported to respond: the CD4+ helpers that direct the response, and the CD8+ killers that destroy infected cells.
  - c2 [human/active] In animals whose thymus gland had been surgically removed, and in cells grown in a dish, thymosin alpha-1 brought immune responses back and made T cells respond
  - c3 [human/active] Trials in people, and the reviews that gather them up, record thymosin alpha-1 being given in conditions where the immune system is worn down, and report cell-d
  - c4 [human/active] Those reviewers describe thymosin alpha-1 as pushing the immune system up rather than damping it down.
  - c9 [human/active] Nothing on this page is medical advice. It is a catalogue that keeps every piece of evidence labelled with how strong it is. Take any decision about thymosin al
  - c10 [human/active] The largest test ever run on thymosin alpha-1 — a 2025 phase 3 randomised trial in 1106 people with sepsis — found no difference in how many died between the pe
- **sorry-status:** planes not merged yet — sorry-status activates after voxel-merge-planes
- **standing objections:** 0 open → https://miscsubjects.com/api/articles/thymosin-alpha-1/discourse
- **verbs:** read free · challenge/attest open · edit/move/consolidate CAS-gated with a rows:VOXEL_* key
- **reads_next:** https://miscsubjects.com/a/philosophy · https://miscsubjects.com/api/articles/thymosin-alpha-1/discourse · https://miscsubjects.com/api/protocol

## Article
- **slug:** `thymosin-alpha-1`
- **title:** Thymosin Alpha-1: Approvals, Trial Record, Dosing and What It Does Not Treat
- **url:** https://miscsubjects.com/a/thymosin-alpha-1
- **register:** essay
- **updated:** 2026-08-04T20:49:04.671Z
- **tags:** peptide, thymosin-alpha-1

## Body

Thymosin alpha-1 is a chain of 28 amino acids that the thymus gland releases into the blood, where it tells immature T cells to finish growing up. The synthetic copy is called thymalfasin, it is sold as Zadaxin, and it is a licensed prescription medicine in roughly 35 countries — which makes it the only compound in this library that a drug regulator anywhere has ever approved.

That single fact reorders everything else, so take the evidence state before anything is argued from it. Most peptides in this library have animal data and a handful of uncontrolled human reports. Thymosin alpha-1 has 63 studies registered on ClinicalTrials.gov, four completed phase 3 programmes, a licensed package insert with a real dosing schedule, and more than 3,000 patients dosed across over 70 studies since 1979. Two of the randomised trials are large and both missed their main endpoint: TESTS, 1,106 adults with sepsis, where 28-day death was 23.4% against 24.1% on placebo; and TRACE, 508 people with severe pancreatitis, where infected dead tissue came out at 15.7% against 18.1%. Two results went the other way: in chronic hepatitis B on its own the odds of clearing the virus and holding it cleared came out 2.87 times placebo, and in a 120-person randomised trial in dialysis patients the drug carried a flu vaccine over the European licensing threshold that the vaccine alone did not reach. One observational study in COVID-19 recorded worse outcomes. The animal record is mice, and its cleanest single result is that the whole effect vanishes in mice bred without the TLR9 receptor. Then the absence that governs this page: across all 63 registered trials there is no tendon, no ligament, no disc, no muscle and no joint. Nothing has been measured in a person for any musculoskeletal problem, and no animal model of one has been run either.

One disclosure, because it should change how you read the rest. The operator of this site has a commercial interest in compounds described here. That is a reason to weigh what is on this page against the sources it cites rather than against its tone, and every claim below carries the source that supports it for exactly that reason.

[[embed:source:w_18bl3rtc]]

## Approved in Beijing, unapproved in Bethesda

Thymalfasin holds marketing approvals for chronic hepatitis B, chronic hepatitis C, use as a vaccine adjuvant in immunocompromised patients, and certain cancers, with the exact indication set varying by country. The United States is not among them. Neither is the European Union.

| Jurisdiction | Status | Indications where approved |
|---|---|---|
| China | Approved; marketed as Zadaxin and by domestic manufacturers | Hepatitis B, immune enhancement, vaccine response, critical-illness adjunct |
| Italy | Approved | Hepatitis B, hepatitis C |
| Roughly 35 countries in total | Approved | Hepatitis B, hepatitis C, vaccine adjuvant, certain cancers, per each national label |
| United States | **Not approved.** No Drugs@FDA entry, no FDA-approved label, no openFDA label record | None |
| European Union | **Not approved** | None |

The manufacturer's own monograph puts the count at "over 30 countries" and states the exclusion in one sentence: "ZADAXIN has not been approved for sale in the United States or Europe." The peer-reviewed literature puts it at "more than 35 countries."

[[embed:source:w_d85m6gah]]

[[embed:source:s1]]

The US absence is not a rejection on the merits. No sponsor has completed a US registration filing. Thymalfasin has held FDA orphan drug designations — for malignant melanoma, chronic active hepatitis B, DiGeorge anomaly with immune defects, and hepatocellular carcinoma. A designation is a development incentive: fee waivers, tax credits, and seven years of market exclusivity if the drug is later approved. It is not an approval, it permits no marketing, and it carries no finding about whether the drug works. Sources that describe those designations as approvals are wrong, and the distinction is the whole of the US position.

## Withdrawn from the danger list is not the same as cleared for use

The entire United States position turns on one table on one FDA page, and the row is easy to misread.

FDA maintains a page titled *Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks*. It carries two tables. The first is Category 2 proper — substances FDA has flagged as posing significant safety risks, which bars compounding under the interim policies. The second is headed *Bulk drug substances nominated but withdrawn*, described as substances "previously in category 2 of the interim policies" that "were withdrawn by the nominators."

Thymosin-alpha 1 sits in the second table, alongside BPC-157, KPV, TB-500, epitalon, semax, selank and DSIP. FDA's recorded concern reads:

> Compounded drugs containing thymosin-alpha-1 (Ta1) may pose significant risk for immunogenicity for certain routes of administration and may have complexities with regard to peptide-related impurities and API characterization. The safety-related information is inadequate for the agency to sufficiently understand the extent of any safety issues raised by the proposed compounded drug.

[[embed:source:w_uzdfttix]]

Three consequences follow, and they are not the same as each other.

Withdrawal is a procedural act by the party who filed the nomination. It removes the substance from the active Category 2 listing. It is not FDA finding the substance safe, and no agency review concluded in the substance's favour.

Absence from Category 2 creates no permission. To be lawfully compounded from a bulk substance under section 503A, a substance must be the subject of an applicable USP or National Formulary monograph, be a component of an FDA-approved drug, or appear on the 503A bulks list. Thymosin alpha-1 is none of the three in the United States. The 503B outsourcing-facility channel is separate, narrower, and does not list it either.

The practical position in the United States is therefore an unapproved drug obtainable only through the grey market or a compounder operating outside the bulks framework. Any source still describing it as "FDA Category 2" is quoting a status the current page no longer assigns to it. That page was last updated 22 April 2026.

## It gives back a signal the thymus stops sending

The thymus is largest in childhood and shrinks from puberty onward. By the sixth decade most of its functional tissue has been replaced by fat, and the output of new naive T cells falls with it. Thymosin alpha-1 is one of the peptides that tissue secretes; circulating levels in healthy adults run between 0.1 and 1 ng/mL and are lower in disease.

The mechanism reads as a chain. The links are not equally well established, and the difference matters.

**Step one — it binds Toll-like receptors on dendritic cells.** This is the anchoring finding and it is demonstrated directly. In mice, thymosin alpha-1 activated plasmacytoid dendritic cells through TLR9 and MyD88, switching on interferon regulatory factor 7 and driving an interferon-alpha and interferon-gamma effector response. Mice lacking TLR9 lost the protection. That is a knockout-confirmed dependency, not a correlation.

[[embed:source:w_e7vuijxz]]

**Step two — the dendritic cell decides what kind of immunity follows.** Dendritic cells read an infection and instruct the rest of the immune system. Priming them through TLR/MyD88 produced Th1-type antifungal resistance in living animals. The same work found thymosin alpha-1 inducing indoleamine 2,3-dioxygenase in dendritic cells — the enzyme that pushes toward tolerance rather than attack.

[[embed:source:w_pptae9m4]]

**Step three — T cells mature and differentiate.** The 1972 characterisation was of a thymic fraction that restored immune function to thymectomised mice. The measurable human version is a rise in CD4+ percentage and a normalising CD4+/CD8+ ratio. A meta-analysis of five randomised trials in severe acute pancreatitis quantified it: CD4+ percentage rose by 4.53 points (95% CI 3.02 to 6.04) and the CD4+/CD8+ ratio by 0.42 (95% CI 0.26 to 0.58). CD8+ counts did not fall significantly, which is the point — the ratio normalised by lifting the deficient arm.

[[embed:source:s7]]

**Step four — natural killer cells and cytotoxic T lymphocytes.** Thymosin alpha-1 modulates NK cell maturation and cytotoxic T lymphocyte responses, and raises MHC class I surface expression on tumour cell lines. The target cell becomes easier to see, not only the effector cell more aggressive.

[[embed:source:w_ekm6tk8i]]

**Step five — reversal of T-cell exhaustion.** In severe COVID-19 patients, treatment was associated with reduced PD-1 and Tim-3 expression on CD8+ T cells and a rise in T-cell receptor excision circles, the standard marker of fresh thymic output. This is observational human data from a retrospective cohort of 76 patients, not a controlled experiment, and it belongs in a different evidentiary tier from step one.

[[embed:source:w_or6weneu]]

What separates this compound from a stimulant is that the same molecule pushes in opposite directions depending on the state it finds. It induces tolerance-promoting IDO in one context and interferon-driven antiviral attack in another. That bidirectionality is why the literature calls it restoration rather than stimulation. It is also why the dose-response is not a straight line, and why the sepsis subgroups below point in opposite directions in different patients.

[[embed:source:s2]]

## Sixty-three registered trials, and the two largest disagree

Sixty-three studies are registered on ClinicalTrials.gov with thymosin alpha-1 as an intervention. The named human record is set out below with the result stated as each trial reported it, including the failures.

| Trial | NCT | n | Population | Dose | Duration | Primary endpoint | Result |
|---|---|---|---|---|---|---|---|
| TESTS — phase 3, quadruple-blind, 22 centres | NCT02867267 | 1,106 | Sepsis-3 adults, 18–85 | 1.6 mg SC every 12 h | ≤7 days | 28-day all-cause mortality | **Missed.** 23.4% vs 24.1% placebo; HR 0.99 (0.77–1.27); P=0.93 |
| ETASS — RCT, single-blind, 6 centres | NCT00711620 | 361 analysed | Severe sepsis | 1.6 mg SC twice daily ×5 d, then daily ×2 d | 7 days | 28-day all-cause mortality | Borderline. 26.0% vs 35.0%; RR 0.74 (0.54–1.02); P=0.062 unstratified, 0.049 log-rank |
| TRACE — phase 4, double-blind, 16 centres | NCT02473406 | 508 | Predicted severe acute necrotising pancreatitis | 1.6 mg SC q12h ×7 d, then daily ×7 d | 14 days | Infected pancreatic necrosis | **Missed.** 15.7% vs 18.1%; difference −2.4% (−7.4 to 5.1); P=0.48 |
| TRACE post-hoc, lymphocyte-stratified | NCT02473406 | 290 of 502 | Same trial, baseline ALC ≥0.8×10⁹/L | as above | 14 days | Infected pancreatic necrosis at 90 d | Positive in subgroup. Adjusted risk difference −0.12 (−0.21 to −0.02); P=0.015 |
| Hepatitis C non-responders — phase 3, 52 European sites | NCT01178996 | 552 | Chronic HCV, prior peg-IFN + ribavirin failure | 1.6 mg SC twice weekly + peg-IFN α-2a + ribavirin | 48 weeks | Sustained virological response at week 72 | Completed July 2009. **No results posted or published** |
| Hepatitis C non-responders, non-cirrhotic — phase 3 | NCT00040027 | 500 | Chronic HCV interferon non-responders | 1.6 mg twice weekly + peg-IFN α-2a | — | Virological response | Completed. **No results posted** |
| Metastatic melanoma — phase 2, dose-ranging, 5 arms | NCT00911443 | 488 | Stage IV melanoma | 1.6, 3.2 or 6.4 mg SC on days 8–11 and 15–18 of each 28-day cycle | ≤6 cycles | Overall tumour response | Responders 7/97, 10/97, 6/98, 12/99 in the four Tα1 arms vs 4/97 control. Median OS 8.6–10.3 months vs 6.6 |
| COVID-19 prevention in dialysis — phase 2 | NCT04428008 | 189 | ESRD on haemodialysis | 1.6 mg SC | 6 months | Number infected with COVID-19 | 5/91 treated vs 7/98 control. Deaths 3/91 vs 7/98. Underpowered for both |
| COVID-19 with lymphocytopenia — phase 2 | NCT04487444 | 56 | Hospitalised, lymphocytopenic | 1.6 mg SC daily ×7 d | 1 week | Time to freedom from respiratory failure | **Terminated** February 2023. No results posted |
| H1N1 vaccine adjuvant pilot | NCT01031966 | 120 enrolled, 94 ITT | ESRD on chronic dialysis | 3.2 mg or 6.4 mg on day −7 and day 0 | 2 doses | Antibody response measured by haemagglutination-inhibition | Positive. CHMP licensing criteria fully met in both Tα1 arms, not in vaccine-only |
| Colorectal cancer adjuvant — phase 3 | NCT05086614 | 2,500 planned | Resected high-risk stage II/III colorectal cancer | 1.6 mg SC twice weekly | 6 months | 3-year disease-free survival | **Recruiting.** Primary completion March 2027 |
| Acute aortic dissection, immune dysregulation | NCT05339529 | 330 | Post-operative acute aortic syndrome | Per protocol | — | Organ dysfunction | Recruiting |
| Vaccine response in older adults — phase 1 | NCT06821100 | 75 | Adults over 65 receiving COVID-19 vaccine | Per protocol | — | Immune response | Recruiting |

[[embed:source:w_vzvtwnky]]

[[embed:source:w_zlvvtukb]]

## Hepatitis is the indication the licences rest on

The approvals were granted on chronic hepatitis B. An independent meta-analysis of 435 patients across randomised controlled trials of thymalfasin monotherapy found a sustained virological response advantage over placebo with an odds ratio of 2.87 (95% CI 1.58–5.22, P=0.0005), and a non-significant trend favouring it over interferon alpha (OR 2.62, 95% CI 0.80–8.56). Across the individual monotherapy studies, disease remission ran 26% to 41%.

[[embed:source:w_d85m6gah]]

Two caveats belong in the same breath. The comparator was interferon or placebo, in an era before tenofovir and entecavir; a 2020 review states plainly that hepatitis B and C treatment with thymosin alpha-1 "has been discontinued in favor of direct antiviral agents." And the two large phase 3 hepatitis C programmes in non-responders — 552 and 500 patients, both completed more than fifteen years ago — have never reported. A completed 552-patient phase 3 with no published outcome is not neutral evidence about a drug; it is a hole where the answer should be.

[[embed:source:w_xmbjsj3u]]

## Sepsis is where it was tested hardest and came up short

ETASS in 2013 was the encouraging trial. 361 patients, 28-day mortality 26.0% on thymosin alpha-1 against 35.0% on control, plus a measurable rise in monocyte HLA-DR — the clearest available marker of reversed immunoparalysis — at day 3 (mean difference 3.9%, 95% CI 0.2–7.6) and day 7 (5.8%, 95% CI 1.0–10.5). The mortality difference did not clear significance on the primary unstratified analysis at P=0.062.

TESTS was built to settle it. 1,106 patients, 22 centres, quadruple-blinded, placebo-controlled, phase 3. It found nothing: 28-day mortality 23.4% against 24.1%, hazard ratio 0.99, P=0.93. No secondary endpoint separated, and no safety endpoint separated either.

The subgroup analysis is where it stops being simply negative. Patients under 60 did worse on the drug (HR 1.67, 1.04–2.67). Patients 60 and over trended better (HR 0.81, 0.61–1.09). Interaction P=0.01. Diabetic patients did better (HR 0.58, 0.35–0.99), non-diabetic patients did not (HR 1.16, 0.87–1.53), interaction P=0.04. These are prespecified subgroups inside a negative trial. They are hypotheses, and a younger patient doing worse on an immune-restoring drug is a hypothesis worth taking seriously in both directions.

A 2025 meta-analysis pooled 11 randomised trials and 1,927 patients. Overall it found a 28-day mortality benefit (OR 0.73, 95% CI 0.59–0.90, P=0.003). That benefit disappeared when restricted to high-quality trials (OR 0.82, P=0.09) and to multicentre trials (OR 0.86, P=0.20). Trial sequential analysis concluded the accumulated sample is still inadequate to answer the question.

[[embed:source:s27]]

## Pancreatitis: the trial missed, and one subgroup did not

TRACE randomised 508 patients with predicted severe acute necrotising pancreatitis, 94.3% of whom required intensive care. Infected pancreatic necrosis occurred in 15.7% of treated patients and 18.1% of placebo patients, P=0.48. New-onset organ failure, bleeding and gastrointestinal fistula were all similar between arms.

[[embed:source:w_0c2625io]]

The post-hoc analysis found what the whole trial did not. Among the 290 patients whose baseline absolute lymphocyte count was at or above 0.8×10⁹/L, thymosin alpha-1 reduced infected necrosis with an adjusted risk difference of −0.12 (95% CI −0.21 to −0.02, P=0.015). Patients between 0.79 and 2.00×10⁹/L benefited most.

[[embed:source:w_cbj4dxj3]]

Read carefully, that is the single most informative result in the file. An immune-restoring drug worked in the patients who still had lymphocytes to restore and did nothing in the patients too depleted to respond. It is post-hoc, it needs prospective confirmation, and it explains why an unselected population produces a null. It also implies that any honest use of this compound starts with a lymphocyte count.

## COVID-19 produced three answers, and one of them was harm

The Wuhan retrospective covered 76 severe cases and reported mortality of 11.11% with treatment against 30.00% without (P=0.044), alongside restored CD8+ and CD4+ counts and reduced exhaustion markers.

[[embed:source:w_or6weneu]]

A five-hospital multicentre cohort of 2,282 patients found the reverse. After adjustment for confounders, thymosin alpha-1 use was associated with a *higher* non-recovery rate (OR 1.5, 95% CI 1.1–2.1, P=0.028), with risk concentrated in patients with SOFA scores of 2 or more, ICU admission, and lower PaO₂/FiO₂. Later initiation was worse than earlier.

[[embed:source:w_q4kpjhai]]

A propensity-matched cohort of 1,388 non-severe patients found no difference in progression to severe disease (2.17% vs 2.71%) or in mortality, but shorter viral shedding (13 vs 16 days, P=0.025) and shorter hospital stay (14 vs 18 days, P<0.001).

[[embed:source:w_vxfrwa56]]

All three are observational and all three are subject to confounding by indication — sicker patients get more drugs. The only randomised study that targeted the lymphocytopenic patients the mechanism predicts should respond was terminated at 56 patients and never reported.

## Vaccine response is the cleanest positive signal in the file

Haemodialysis patients mount poor antibody responses to influenza vaccine. In the pilot trial, patients given the adjuvanted H1N1 vaccine alone did not meet the CHMP licensing criteria for seroconversion, seroprotection and geometric mean ratio. Patients given the vaccine plus 3.2 mg or 6.4 mg of thymosin alpha-1 on day −7 and day 0 met all three. No adverse event was attributed to the peptide, and no change appeared in haematology or blood chemistry.

[[embed:source:w_23spjiq3]]

This is 94 patients in an intention-to-treat analysis, in a population defined by immune failure, in a pilot study. It is also the one result where the drug did the specific thing its mechanism predicts, in humans, judged against a prespecified regulatory standard rather than an author's own endpoint.

## The cancer file is adjuvant work with one real trial still running

The melanoma dose-ranging study is the largest completed oncology dataset: 488 patients across five arms, responses in 6 to 12 patients per thymosin arm against 4 of 97 in the dacarbazine-plus-interferon control, and median overall survival of 8.6 to 10.3 months against 6.6. It was a phase 2 designed to select a dose, not to prove survival, and no phase 3 followed it in the nineteen years since it started.

[[embed:source:w_omh8z65r]]

The trial that would settle the oncology question is enrolling now: 2,500 patients with resected high-risk stage II and III colorectal cancer, randomised to 1.6 mg twice weekly for six months or to no thymosin, with three-year disease-free survival as the primary endpoint and primary completion in March 2027.

[[embed:source:w_dkfbbahz]]

## Every trial population is an infection, an organ failure or a cancer, and not one of them is a back

Every trial population above is a hepatitis patient, a septic ICU patient, a pancreatitis patient, a cancer patient, or a dialysis patient. Not one is a back-pain patient. There is no musculoskeletal indication, no tendon, ligament, disc or muscle model, and no mechanism connecting T-cell maturation to tissue repair.

| What brings a person to look this up | What the human record actually covers | Strength of the connection |
|---|---|---|
| Recurrent infection, slow recovery from every cold | Vaccine-response pilot in dialysis patients; hepatitis approvals; 3,000-patient safety file | Moderate, and only by extrapolation from immunocompromised populations |
| Documented immunosuppression with a measured low-normal lymphocyte count | TRACE subgroup: the effect appeared where lymphocytes were preserved but suppressed | Moderate. Post-hoc, and it requires the blood test to identify |
| Post-viral fatigue after a confirmed infection | No completed randomised trial. The COVID file is acute hospitalised disease and it contradicts itself | Absent |
| Chronic inflammatory load in a chronic-pain patient | CRP fell 30.12 mg/L in the lower-dose arms of the pancreatitis meta-analysis — in patients with necrotising pancreatitis in intensive care | Absent for this population |
| Immune-related fatigue with no diagnosis and no abnormal labs | No trial, no endpoint, no measurement | Absent |
| Tendinopathy, disc pain, muscle strain, joint repair | No model, no trial, no proposed mechanism | Absent. The extrapolation is unsupported |
| Post-adjustment soreness | Nothing | Absent |
| Hashimoto's, MCAS, ankylosing spondylitis, other autoimmunity | No trial. The mechanism cuts both ways — tolerance in one context, interferon-driven attack in another | Absent, and the self-reports below include people who got measurably worse |

The one row the record can defend is the immune row, in a person with documented immune compromise, and even that defence is an off-label extrapolation from populations that do not look like that person. Selling thymosin alpha-1 for musculoskeletal repair is a claim that nothing in 63 trials supports.

## Dosing, and the arithmetic behind the syringe

The licensed product is a 1.6 mg lyophilised vial supplied with 1.0 mL of Sterile Water for Injection. Reconstituted, that is 1.6 mg/mL, and the whole vial is one dose. The approved hepatitis B regimen is 1.6 mg (900 µg/m²) subcutaneously twice a week for 6 to 12 months. Patients under 40 kg receive 40 µg/kg.

[[embed:source:w_dt6aln8r]]

| Setting | Dose | Frequency | Duration |
|---|---|---|---|
| Hepatitis B — approved label | 1.6 mg SC | Twice weekly | 6–12 months |
| Hepatitis C — phase 3 protocol | 1.6 mg SC | Twice weekly | 48 weeks |
| Sepsis — TESTS | 1.6 mg SC | Every 12 hours | ≤7 days |
| Sepsis — ETASS | 1.6 mg SC | Twice daily ×5 d, then daily ×2 d | 7 days |
| Necrotising pancreatitis — TRACE | 1.6 mg SC | Every 12 h ×7 d, then daily ×7 d | 14 days |
| Colorectal adjuvant — phase 3 | 1.6 mg SC | Twice weekly | 6 months |
| Metastatic melanoma — phase 2 | 1.6, 3.2 or 6.4 mg SC | Days 8–11 and 15–18 of a 28-day cycle | ≤6 cycles |
| Influenza vaccine adjuvant | 3.2 or 6.4 mg SC | Day −7 and day 0 | 2 doses |

The critical-illness regimens run at 3.2 mg per day — twice the hepatitis dose, for one to two weeks. The vaccine regimen runs up to 6.4 mg in a single dose. The cumulative safety record spans 1 mg to 16 mg per dose, and 0.6 to 9.6 mg/m². There is no dose ceiling hiding in that range. There is also nothing showing that a larger dose does more for a stable outpatient.

### Reconstitution, shown as arithmetic

Grey-market vials come as 5 mg or 10 mg of lyophilised powder, not 1.6 mg, so the arithmetic has to be done rather than read off a label.

Concentration in mcg per mL = total micrograms in the vial ÷ millilitres of bacteriostatic water added.
A U-100 insulin syringe holds 1.0 mL across 100 units, so one unit is 0.01 mL, and micrograms per unit = concentration ÷ 100.

Worked: a 10 mg vial holds 10,000 mcg. Add 4.0 mL of bacteriostatic water. 10,000 ÷ 4.0 = 2,500 mcg/mL. 2,500 ÷ 100 = 25 mcg per unit. A 1.6 mg dose is 1,600 ÷ 25 = 64 units on the barrel.

| Vial | Bacteriostatic water added | Concentration | Mcg per unit | Units for 1.6 mg | Full 1.6 mg doses per vial |
|---|---|---|---|---|---|
| 5 mg (5,000 mcg) | 2.0 mL | 2,500 mcg/mL | 25 | 64 | 3, with 200 mcg left over |
| 5 mg (5,000 mcg) | 2.5 mL | 2,000 mcg/mL | 20 | 80 | 3 |
| 5 mg (5,000 mcg) | 5.0 mL | 1,000 mcg/mL | 10 | 160 — two injections | 3 |
| 10 mg (10,000 mcg) | 2.0 mL | 5,000 mcg/mL | 50 | 32 | 6, with 400 mcg left over |
| 10 mg (10,000 mcg) | 4.0 mL | 2,500 mcg/mL | 25 | 64 | 6 |
| 10 mg (10,000 mcg) | 5.0 mL | 2,000 mcg/mL | 20 | 80 | 6 |

At 5,000 mcg/mL — a 10 mg vial in 2.0 mL, the concentration that keeps every trial dose inside one syringe — the conversion is:

| Dose | Micrograms | Units on a U-100 barrel |
|---|---|---|
| 0.25 mg | 250 | 5 |
| 0.5 mg | 500 | 10 |
| 0.8 mg | 800 | 16 |
| 1.0 mg | 1,000 | 20 |
| 1.6 mg | 1,600 | 32 |
| 3.2 mg | 3,200 | 64 |
| 6.4 mg | 6,400 | 128 — two injections |

Below about five units, graduation error on a U-100 barrel starts to dominate the dose, which is the argument for more diluent at the sub-milligram tiers and less at 1.6 mg and above.

Route is subcutaneous in every trial and on every label. Sites are the abdomen at least two inches from the navel, the outer thigh, or the back of the upper arm, rotated between doses. Nothing in the record supports taking this peptide into a muscle, into a vein or by mouth outside a study protocol.

Bring the vial to room temperature before adding water. Run the water down the inside wall rather than jetting it onto the powder. Swirl until dissolved and never shake — shear at the air-liquid interface unfolds peptides and makes them clump, and that clumping is the exact mechanism FDA named when it warned about the immune system reacting to the drug.

### Storage, and the difference the diluent makes

| State | Temperature | Practical shelf life |
|---|---|---|
| Sealed lyophilised vial | 2–8 °C, protected from light | To the manufacturer's date |
| Reconstituted with Sterile Water for Injection — the licensed diluent | — | Use immediately. No preservative present |
| Reconstituted with bacteriostatic water, 0.9% benzyl alcohol | 2–8 °C | About four weeks, set by the preservative rather than by the peptide |
| Reconstituted, held at room temperature | 20–25 °C | Hours to days. Treat as compromised |
| Reconstituted, frozen | −20 °C | Avoid. Freeze-thaw aggregates peptides |

The licensed insert says use immediately because the supplied diluent is preservative-free. A multi-dose vial reconstituted with bacteriostatic water is a different object running a different clock.

### Timelines

Peak serum concentration is reached about 2 hours after a subcutaneous dose, the elimination half-life is about 2 hours, and 31% to 60% of the dose is recovered in urine. The drug leaves the blood the same day. Everything that persists is downstream of what it did to cells, which is why the schedules are twice weekly rather than daily.

| What was measured | When it read out in the trials |
|---|---|
| Monocyte HLA-DR improvement — ETASS | Days 3 and 7 |
| CD4+ percentage and CD4+/CD8+ ratio change | Within the 7–14 day critical-illness courses |
| Vaccine seroconversion — H1N1 pilot | Day 21 after vaccination, dosed day −7 and day 0 |
| Hepatitis B sustained virological response | 6–12 months of dosing, assessed 6 months after treatment |
| Hepatitis C sustained virological response | Week 72, after 48 weeks of dosing |
| Colorectal disease-free survival | 3 years, after 6 months of dosing |

## The safety record is the longest in this library, which is not the same as no risk

Most compounds in this library have no human safety file at all. This one has a specific, quantified record.

Since 1979, thymalfasin has been given to more than 3,000 patients in over 70 clinical studies, at doses from 1 mg to 16 mg, for periods from a single day to 18 months. The monograph's summary sentence is that "no serious adverse experiences have been observed." Patients as old as 101 and children as young as 13 months have been dosed. Patients with decompensated liver disease and patients on haemodialysis tolerated it.

[[embed:source:w_d85m6gah]]

The label puts drug-related adverse events at under 1% across all indications and describes them as "infrequent and mild, consisting primarily of local discomfort at the injection site, and rare instances of erythema, transient muscle atrophy, polyarthralgia combined with hand edema, and rash." It is contraindicated in hypersensitivity to the drug or its components.

[[embed:source:w_dt6aln8r]]

The controlled trials support that. TESTS randomised 1,106 patients and reported no safety outcome differing significantly between drug and placebo. TRACE randomised 508 and found no difference in bleeding, fistula or new organ failure. The H1N1 pilot attributed no adverse event to the peptide. In the dialysis prevention trial, serious adverse events were 28 of 91 on treatment against 26 of 98 on control, and deaths were 3 of 91 against 7 of 98.

[[embed:source:w_jzf25pn3]]

Preclinical toxicity never reached a maximum tolerated dose. Single subcutaneous doses up to 20 mg/kg in mice, rats and marmosets — more than 800 times the human 1.6 mg dose by weight — produced no drug-related toxicity, as did repeat dosing at 6 mg/kg/day for 13 weeks.

Three qualifications matter more than the reassurance.

**Immune activation can itself be the adverse event.** A 29-year-old man with nasopharyngeal carcinoma received a single 1.6 mg subcutaneous dose eleven days after the checkpoint inhibitor sintilimab. Within 48 hours he had fever of 39–40.5 °C, facial rash and oedema, progressive hypoxaemia with interstitial pulmonary oedema, AST of 742 U/L, and a prothrombin time of 23.2 seconds. He required 160 mg of intravenous methylprednisolone daily and was discharged on day 33. He later tolerated a sintilimab rechallenge without recurrence, which points the causal finger at the peptide rather than the checkpoint inhibitor.

[[embed:source:w_c958vpgi]]

**The COVID cohort recorded worse outcomes, not merely absent benefit.** An adjusted odds ratio of 1.5 for non-recovery in the sicker patients is a harm signal, and the mechanism is plausible: adding immune activation to a hyperinflammatory state is not obviously safe.

**FDA's stated concern is manufacturing, not what the drug does in the body.** The risk of the immune system reacting to the drug, raised by clumping and by peptide-related impurities, is a supply-chain problem. The 3,000-patient safety record belongs to a pharmaceutical product made to a licensed specification. A grey-market vial carrying a vendor's own certificate of analysis is not that product, and a cloudy reconstitution is a visible sign of the exact aggregation the agency named.

## What people using it outside the trials report

These are self-reports with dates and permalinks, gathered from public discussion. They are not evidence of whether it works, they are not filtered for anything, and they are here because they show what the experience looks like and how often it goes badly.

[[embed:source:s8]]

[[embed:source:s61]]

[[embed:source:s75]]

[[embed:source:s41]]

The most consistent thread across the positive reports is a flu-like reaction in the first days, which users describe as the immune system waking up.

[[embed:source:s14]]

The negative reports describe the same reaction without the recovery on the other side of it.

[[embed:source:s63]]

[[embed:source:s37]]

[[embed:source:s13]]

Two reports concern measured markers rather than symptoms, in the same condition, and they disagree.

[[embed:source:s38]]

[[embed:source:s59]]

One comment states the risk in exactly the terms the mechanism implies.

[[embed:source:s77]]

And one describes the physical failure mode that FDA's warning is about.

[[embed:source:s84]]

## Proven, unproven, unknown

| Status | Claim |
|---|---|
| Proven | Approved as thymalfasin in roughly 35 countries for hepatitis B, hepatitis C and vaccine adjuvant use |
| Proven | Not approved in the United States or the European Union; no Drugs@FDA entry and no FDA label |
| Proven | Listed in FDA's "nominated but withdrawn" bulk-substances table, not in Category 2, and on neither the 503A nor the 503B bulks list |
| Proven | Acts through TLR9/MyD88/IRF7 on plasmacytoid dendritic cells; the effect is abolished in TLR9-deficient mice |
| Proven | Raises CD4+ percentage by 4.53 points and the CD4+/CD8+ ratio by 0.42 in critically ill humans |
| Proven | Peak serum at about 2 hours, elimination half-life about 2 hours, 31–60% urinary recovery |
| Proven | Sustained virological response advantage in chronic hepatitis B monotherapy, OR 2.87 (1.58–5.22) |
| Proven | Met the European regulator's antibody-response criteria as an influenza vaccine adjuvant in haemodialysis patients where vaccine alone did not |
| Proven | No mortality benefit in sepsis in a 1,106-patient placebo-controlled phase 3 |
| Proven | No reduction in infected pancreatic necrosis in a 508-patient placebo-controlled trial |
| Proven | Drug-related adverse events under 1% across indications in the licensed record, predominantly injection-site discomfort |
| Unproven | Any benefit in post-viral fatigue, chronic fatigue, MCAS, or any autoimmune condition — no completed randomised trial exists |
| Unproven | Benefit in COVID-19. Three observational studies, three different answers, one of them harm |
| Unproven | Whether the pancreatitis lymphocyte-count subgroup effect survives prospective testing |
| Unproven | Whether it improves disease-free survival in colorectal cancer; that trial reads out in 2027 |
| Unknown | The outcome of two completed phase 3 hepatitis C trials totalling 1,052 patients, never reported |
| Unknown | Any effect on tendon, ligament, disc, muscle or joint tissue. No model, no trial, no mechanism |
| Unknown | The correct dose for an outpatient with no diagnosed immune deficiency |
| Unknown | Whether grey-market material matches the pharmaceutical product that generated the safety record |

*Thymosin alpha-1 is not an approved drug in the United States and is not lawfully available there through the bulk-compounding pathways. Nothing here is a dosing or treatment recommendation.*

The sibling objects for this page, each one inspectable on its own terms:

[[embed:kpv]]

[[embed:ghk-cu]]

[[embed:bpc-157]]

[[embed:dsip]]

[[embed:tb-500]]


## Claims (48 of 105 ranked)

- **c97** [mechanistic w=0.3] Hash-chaining the sources proves the record has not been tampered with. It says nothing about whether any of it is true. Most of what is gathered here is laboratory work and forum posts, and the human trial data on thymosin alpha-1 is thin. There is no dose and no protocol on this page, because a catalogue is all it is.
  - who_claims: miscsubjects protocol
  - slot: limitations
- **c1** [human w=0.8] Thymosin alpha-1 — Ta1 for short, written Tα1 in the papers and TA-1 in most forum posts — attaches to sensors called Toll-like receptors that sit on dendritic cells, the scout cells whose job is to show the rest of the immune system what an infection looks like.
  - who_claims: system/unknown
  - slot: mechanism
  - sources: s1
- **c2** [human w=0.8] In animals whose thymus gland had been surgically removed, and in cells grown in a dish, thymosin alpha-1 brought immune responses back and made T cells respond more strongly.
  - who_claims: system/unknown
  - slot: what_is_known
  - sources: s1, s2
- **c3** [human w=0.8] Trials in people, and the reviews that gather them up, record thymosin alpha-1 being given in conditions where the immune system is worn down, and report cell-driven immunity coming back.
  - who_claims: system/unknown
  - slot: what_is_known
  - sources: s1, s3
- **c4** [human w=0.8] Those reviewers describe thymosin alpha-1 as pushing the immune system up rather than damping it down.
  - who_claims: system/unknown
  - slot: what_is_known
  - sources: s1
- **c9** [human w=0.8] Nothing on this page is medical advice. It is a catalogue that keeps every piece of evidence labelled with how strong it is. Take any decision about thymosin alpha-1 to a doctor who knows your history.
  - who_claims: system/protocol
  - slot: disclaimer
- **c13** [human w=0.8] A 2025 systematic review pooled the trials of thymosin alpha-1 in severe acute pancreatitis, the sudden and dangerous inflammation of the pancreas.
  - who_claims: grok/grok-4.3
  - slot: what_is_known
  - sources: s7
- **c17** [human w=0.8] A 2026 consumer health write-up on thymosin alpha-1 walks through its uses and its safety record and folds in the 2025 sepsis trial result. It is a summary of other people's work, with no new data in it.
  - who_claims: grok/grok-4.3
  - slot: what_is_known
  - sources: s11
- **c27** [human w=0.8] That 2025 pooling of the severe acute pancreatitis trials reported less inflammation and fewer infections in the people given thymosin alpha-1, and put it down to the immune system being steadied.
  - who_claims: grok/grok-4.3
  - slot: what_is_known
  - sources: s21
- **c33** [human w=0.8] A 2025 pooled analysis of 11 randomised trials found fewer deaths at 28 days among sepsis patients given thymosin alpha-1 than among those who were not.
  - who_claims: grok/grok-4.3
  - slot: what_is_known
  - sources: s27
- **c42** [human w=0.8] A 2025 review of thymosin alpha-1 in ageing covers the same ground and adds two more effects: it calms inflammation, and it mops up the reactive molecules that damage cells. The review pulled existing work together rather than adding data of its own.
  - who_claims: grok/grok-4.3
  - slot: what_is_known
  - sources: s36
- **c49** [human w=0.8] A 2025 updated pooling of the sepsis trials landed the other way and concluded that thymosin alpha-1 lowers the number of people who die within 28 days. Two poolings read much the same trials and disagreed, and the single largest trial found nothing at all.
  - who_claims: grok/grok-4.3
  - slot: what_is_known
  - sources: s43
- **c61** [human w=0.8] Nobody has followed people taking thymosin alpha-1 long enough to say what happens after years of it. The safety record is short-term only.
  - who_claims: kimi-collaborator
  - slot: what_is_unknown
  - sources: s1
- **c300** [human w=0.8] Once those scout cells are switched on, they finish the training of T cells, the white blood cells that kill infected cells and give orders to the rest of the immune response.
  - who_claims: system/unknown
  - slot: mechanism
  - sources: s1
- **c301** [human w=0.8] Both main kinds of T cell are reported to respond: the CD4+ helpers that direct the response, and the CD8+ killers that destroy infected cells.
  - who_claims: system/unknown
  - slot: mechanism
  - sources: s1
- **c302** [human w=0.8] That signal vanished when the same 2025 authors looked only at the better-run trials, and again when they looked only at the trials spread across several hospitals. In those, deaths at 28 days were the same either way, and the trials disagreed with each other enough that the authors would not call the overall result settled.
  - who_claims: grok/grok-4.3
  - slot: what_is_known
  - sources: s27
- **c63** [mechanistic w=0.4] The account of thymosin alpha-1 working through Toll-like receptors on the scout cells is the standard one, but which receptor it binds, and what happens inside the cell afterwards, has never been worked all the way out. The mechanism is a sketch, not a map.
  - who_claims: kimi/moonshot-v1-8k (adversary)
- **c96** [runtime w=0.35] Thymosin alpha-1 is a lab-made copy of a small signalling molecule released by the thymus, the gland behind the breastbone where the immune system's T cells are trained. This page is a catalogue of what has been published and posted about it, with every source hash-chained so the record cannot be quietly altered afterwards. Nothing on it is a clinical recommendation.
  - who_claims: miscsubjects protocol
  - slot: what_it_is
- **c59** [mechanistic w=0.3] A 2025 study looked at thymosin alpha-1 given alongside other treatment for liver cancer.
  - who_claims: grok/grok-4.3
  - slot: what_is_known
  - sources: s53
- **c25** [anecdotal w=0.3] One person felt sick for a while on thymosin alpha-1 and then stronger, and put it down to the immune system going after infections that had been sitting quietly in the background.
  - who_claims: grok/grok-4.3
  - slot: who_claims_what
  - sources: s19
- **c46** [anecdotal w=0.3] One person reported more dreaming sleep and more deep sleep on thymosin alpha-1.
  - who_claims: grok/grok-4.3
  - slot: who_claims_what
  - sources: s40
- **c48** [anecdotal w=0.3] The same poster wrote that each dose of thymosin alpha-1 clears their long COVID symptoms for roughly 48 hours, after which the symptoms come back.
  - who_claims: grok/grok-4.3
  - slot: who_claims_what
  - sources: s42
- **c54** [anecdotal w=0.3] A 2026 post files thymosin alpha-1 into a list of peptides that act on the immune system. That is a filing decision, not a finding.
  - who_claims: grok/grok-4.3
  - slot: who_claims_what
  - sources: s48
- **c77** [anecdotal w=0.3] One person recovering from long COVID and a bad reaction to a vaccine posted that thymosin alpha-1 stopped their decline and cut down their muscle spasms.
  - who_claims: grok-4.3
  - slot: who_claims_what
  - sources: s68
- **c78** [anecdotal w=0.3] One person endorsed thymosin alpha-1 on the strength of their own experience and their reading, and said the side effects were slight.
  - who_claims: grok-4.3
  - slot: who_claims_what
  - sources: s69
- **c84** [anecdotal w=0.3] Another said thymosin alpha-1, taken only when they needed it, cleared up their sinus infection.
  - who_claims: grok-4.3
  - slot: who_claims_what
  - sources: s75
- **c305** [anecdotal w=0.3] The same person reported steadier daily function and a calmer autonomic nervous system — the part that runs heart rate, blood pressure and digestion without you thinking about it.
  - who_claims: grok-4.3
  - slot: who_claims_what
  - sources: s68
- **c10** [human w=0.8] The largest test ever run on thymosin alpha-1 — a 2025 phase 3 randomised trial in 1106 people with sepsis — found no difference in how many died between the people given the peptide and the people given a dummy injection.
  - who_claims: grok/grok-4.3
  - slot: what_is_known
  - sources: s4
- **c11** [human w=0.8] A 2024 review holds thymosin alpha-1 up as a case of a drug found by watching what it does to whole cells and whole animals, rather than by aiming at a known target first.
  - who_claims: grok/grok-4.3
  - slot: what_is_known
  - sources: s5
- **c12** [human w=0.8] A trial registered for 2025 and onwards is testing whether thymalfasin — the pharmaceutical name for thymosin alpha-1 — makes a COVID booster work better in older adults. It is still running, so there is no result to read.
  - who_claims: grok/grok-4.3
  - slot: what_is_known
  - sources: s6
- **c15** [human w=0.8] A 2025 review gathered up the work on thymosin alpha-1 and the immune decline that comes with age, including its use to make vaccines take better in older people.
  - who_claims: grok/grok-4.3
  - slot: what_is_known
  - sources: s9
- **c26** [human w=0.8] A registered trial gave thymosin alpha-1 to people recovering from COVID-19 whose lymphocyte count — the number of immune cells circulating in the blood — had fallen very low.
  - who_claims: grok/grok-4.3
  - slot: what_is_known
  - sources: s20
- **c29** [human w=0.8] A small 2025 study, with everyone involved knowing who was getting what, gave thymosin alpha-1 to people with common variable immune deficiency — a lasting shortage of antibodies — and reported their low mood lifting. It was a first look, not a test.
  - who_claims: grok/grok-4.3
  - slot: what_is_known
  - sources: s23
- **c38** [human w=0.8] A 2026 review argues that thymosin alpha-1 helps a shrunken thymus gland get back to making T cells, and points to COVID-19 as the setting where that was watched most closely.
  - who_claims: grok/grok-4.3
  - slot: what_is_known
  - sources: s32
- **c39** [human w=0.8] A 2025 pooling of 5 randomised trials covering 706 people with severe acute pancreatitis found higher counts of CD4+ helper T cells — the white cells that direct an immune response — in the people given thymosin alpha-1.
  - who_claims: grok/grok-4.3
  - slot: what_is_known
  - sources: s33
- **c56** [human w=0.8] A registered trial is following sepsis survivors who were given thymosin alpha-1, to see how they are doing long after they left hospital. It is listed as ongoing, so there is no result yet.
  - who_claims: grok/grok-4.3
  - slot: what_is_known
  - sources: s50
- **c57** [human w=0.8] A 2025 study reported that thymosin alpha-1 raised the number of T cells circulating in the patients who received it.
  - who_claims: grok/grok-4.3
  - slot: what_is_known
  - sources: s51
- **c58** [human w=0.8] A registered trial pairs thymosin alpha-1 with ulinastatin, a drug that blocks the inflammation-driving enzymes released during injury, in acute aortic syndrome — a sudden tear in the wall of the body's main artery.
  - who_claims: grok/grok-4.3
  - slot: what_is_known
  - sources: s52
- **c303** [human w=0.8] In that same 706-patient pool, the balance between helper and killer T cells shifted back towards where it sits in a healthy person.
  - who_claims: grok/grok-4.3
  - slot: what_is_known
  - sources: s33
- **c304** [human w=0.8] At the lower doses in that pool, C-reactive protein — the standard blood marker of inflammation — came down, and fewer people went on to develop infections outside the pancreas.
  - who_claims: grok/grok-4.3
  - slot: what_is_known
  - sources: s33
- **c28** [mechanistic w=0.3] A 2025 study put thymosin alpha-1 onto tumour cell lines and onto separate populations of immune cells in a dish, and recorded how each one responded.
  - who_claims: grok/grok-4.3
  - slot: what_is_known
  - sources: s22
- **c37** [mechanistic w=0.3] A 2026 study combined interleukin-15, an immune signalling protein, with thymosin alpha-1 in liver cancer, and reported fewer worn-out CD8+ killer T cells and a stronger attack on the tumour.
  - who_claims: grok/grok-4.3
  - slot: what_is_known
  - sources: s31
- **c55** [mechanistic w=0.3] The same 2026 interleukin-15 and thymosin alpha-1 work is catalogued here twice, because the paper was listed in two places. It is one study reporting worn-out T cells in liver cancer being pushed back towards working order, not two.
  - who_claims: grok/grok-4.3
  - slot: what_is_known
  - sources: s49
- **c14** [anecdotal w=0.3] One person who had been ill with long COVID for years posted that they improved a great deal after starting thymosin alpha-1.
  - who_claims: grok/grok-4.3
  - slot: who_claims_what
  - sources: s8
- **c18** [anecdotal w=0.3] A 2026 short video asks whether thymosin alpha-1 and peptides like it do anything at all for autoimmune conditions. It is talk, not data.
  - who_claims: grok/grok-4.3
  - slot: who_claims_what
  - sources: s12
- **c19** [anecdotal w=0.3] One person reported swollen lymph nodes 2 weeks into thymosin alpha-1, and posted it as a warning to others.
  - who_claims: grok/grok-4.3
  - slot: who_claims_what
  - sources: s13
- **c20** [anecdotal w=0.3] Another read their own flu-like symptoms on thymosin alpha-1 as the immune system waking up. They said the symptoms came in waves, and that each wave left them better off than before.
  - who_claims: grok/grok-4.3
  - slot: who_claims_what
  - sources: s14
- **c21** [anecdotal w=0.3] One person reported their eczema calming down while they were on thymosin alpha-1.
  - who_claims: grok/grok-4.3
  - slot: who_claims_what
  - sources: s15

## Voxel graph (105 atoms · 217 edges)
- full graph: https://miscsubjects.com/api/articles/thymosin-alpha-1/voxels

## Article constitution

- full: https://miscsubjects.com/api/articles/constitution

## Source ledger (40 of 107)
- chain valid: yes · head: `deb365464c96fee8`

### s1 · review · ok
- title: Thymosin alpha 1: A comprehensive review of the literature
- url: https://pmc.ncbi.nlm.nih.gov/articles/PMC7747025/
- summary: 2020 review covering background, mechanisms, and clinical uses in immune contexts.
- quote: Thymosin alpha 1 is a peptide naturally occurring in the thymus that has long been recognized for modifying, enhancing, and restoring immune function.
- claim_ids: c1, c2, c3, c4, c61
- hash: `c8865aacafa144a2`

### s2 · pubmed · ok
- title: Immune Modulation with Thymosin Alpha 1 Treatment
- url: https://pubmed.ncbi.nlm.nih.gov/27450734/
- summary: 2016 review on preclinical and clinical immune modulation.
- quote: Thymosin alpha 1 (Ta1) is a peptide originally isolated from thymic tissue as the compound responsible for restoring immune function to thymectomized mice.
- claim_ids: c2
- hash: `3a2c49cdbadc8c73`

### s3 · review · ok
- title: Comprehensive Review of the Safety and Efficacy of Thymosin Alpha 1 in Human Clinical Trials
- url: https://pubmed.ncbi.nlm.nih.gov/38308608/
- summary: 2024 review of human trials and safety.
- quote: This study aims to assess the safety and efficacy of Thymosin Alpha 1 (Tα1) through a comprehensive narrative review of clinical studies involving over 11 000 human subjects in more than 30 trials.
- claim_ids: c3
- hash: `62e0108ba1db6835`

### s4 · clinical_trial · http_403
- title: The efficacy and safety of thymosin α1 for sepsis (TESTS): multicentre, double blinded, randomised, placebo controlled, phase 3 trial
- url: https://www.bmj.com/content/388/bmj-2024-082583
- summary: Large 2025 phase 3 RCT (n=1106) showing no significant mortality benefit of thymosin α1 in sepsis patients.
- quote: This trial found no clear evidence to suggest that thymosin α1 decreases 28 day all cause mortality in adults with sepsis.
- claim_ids: c10
- hash: `1370e624ff7f4342`

### s5 · review · ok
- title: Phenotypic drug discovery: a case for thymosin alpha-1
- url: https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2024.1388959/full
- summary: 2024 review framing thymosin alpha-1 as example of phenotypic drug discovery with broad immunomodulatory applications.
- quote: This article explores the experiences of researchers testing the effect of a thymic peptide hormone, thymosin alpha-1, in preclinical and clinical settings.
- claim_ids: c11
- hash: `938ad57612eecfe6`

### s6 · clinical_trial · ok
- title: Thymalfasin (Thymosin Alpha 1; Ta1) as an Enhancer of Vaccine Response Among Older Adults Receiving Booster Doses of COVID-19 Vaccine
- url: https://clinicaltrials.gov/study/NCT06821100
- summary: Ongoing/2025+ trial investigating thymalfasin for enhancing COVID vaccine response in older adults.
- quote: This research study will test the safety and possible harms of Ta1 when it is given to people at different dose levels before COVID-19 vaccination.
- claim_ids: c12
- hash: `fc889eeca93b27d2`

### s7 · review · ok
- title: Thymosin alpha 1 alleviates inflammation and prevents infection in patients with severe acute pancreatitis through immune regulation: a systematic review and meta-analysis
- url: https://pubmed.ncbi.nlm.nih.gov/40599771/
- summary: 2025 systematic review/meta-analysis on Tα1 for severe acute pancreatitis.
- quote: Thymosin alpha 1 (Tα1) is an important immunomodulatory agent in clinical practice, but there is a lack evidence to prove its effectiveness in improving the condition of SAP patients.
- claim_ids: c13
- hash: `d5b3bd78fd9f4c74`

### s8 · reddit · ok
- title: 5 Years Long Covid - Thymosin Alpha 1 Peptide - WOW!
- url: https://www.reddit.com/r/covidlonghaulers/comments/1r5ekd8/5_years_long_covid_thymosin_alpha_1_peptide_wow/
- summary: User anecdote reporting significant improvement in long COVID symptoms after starting TA-1 peptide.
- quote: I am now testing Thymosin Alpha 1 Peptide and I have to say WOW! This peptide brings me back to life.
- claim_ids: c14, c62
- hash: `3e5ab07568cb6fa3`

### s9 · review · http_403
- title: Aging and Thymosin Alpha-1
- url: https://www.mdpi.com/1422-0067/26/23/11470
- summary: 2025 review on thymosin alpha-1 for aging-related immune decline and vaccine enhancement.
- quote: Preclinical and clinical studies show that Tα1 can improve vaccine response in the elderly and mitigate immunosenescence.
- claim_ids: c15
- hash: `90d4f5cda865c21e`

### s10 · clinical_trial · ok
- title: Thymosin Alpha 1 Combined With Anti-PD-1 Monoclonal Antibody in Elderly Patients With Advanced Melanoma
- url: https://clinicaltrials.gov/study/NCT07644897
- summary: New 2026 clinical trial testing thymosin alpha 1 combined with anti-PD-1 for advanced melanoma in elderly patients.
- quote: Primary Objective: To evaluate the effectiveness of Thymosin Alpha-1 combined with PD-1 monoclonal antibody in elderly patients with advanced melanoma .
- claim_ids: c5
- hash: `e5e1e222ffd54fd3`

### s11 · review · ok
- title: Thymosin Alpha-1 Peptide: Benefits and Safety [2026]
- url: https://www.innerbody.com/thymosin-alpha-1-peptide
- summary: 2026 comprehensive article reviewing uses, safety, and recent 2025 sepsis trial results for thymosin alpha-1.
- quote: In contrast to those findings, a placebo-controlled trial from early 2025 with over 1,000 subjects found “no clear evidence” that TA-1 decreased 28-day all-cause mortality in adults with sepsis.
- claim_ids: c17
- hash: `e8f5edcd020b4451`

### s12 · youtube · ok
- title: Autoimmune Peptides: Just Hype? (Thymosin Alpha-1 ...
- url: https://www.youtube.com/shorts/_3M2gu4kG68
- summary: 2026 YouTube short discussing thymosin alpha-1 for autoimmune conditions.
- quote: Thymosin Alpha-1 helps recalibrate immune function so your body stops attacking itself while still defending against infections.
- claim_ids: c18
- hash: `782d884dc34110bd`

### s13 · reddit · ok
- title: be careful about thymosin alpha-1 : r/cfs
- url: https://www.reddit.com/r/cfs/comments/1nl65vu/be_careful_about_thymosin_alpha1/
- summary: User reports swollen lymph nodes as a negative side effect after 2 weeks on TA-1.
- quote: I am having the same problems with TA-1 I just connected the dots after 2 weeks of being on TA-1 my lymph nodes are swollen in my neck ...
- claim_ids: c19
- hash: `196082d97ac04d7d`

### s14 · reddit · ok
- title: Anyone get side effects/an immune reaction to Thymosin- ...
- url: https://www.reddit.com/r/covidlonghaulers/comments/1pbotcz/anyone_get_side_effectsan_immune_reaction_to/
- summary: User describes initial flu-like symptoms as part of positive immune activation, followed by overall improvement after waves.
- quote: Im 2 weeks into TA-1 , its working as expected. Immune activation/rebalancing - clearing out virus/viral debris my body was unable to deal with before (Feels like a bad cold/minor flu).
- claim_ids: c20
- hash: `cb1cd196b18a80c1`

### s15 · reddit · ok
- title: A Complete Guide for Thymosin Alpha 1
- url: https://www.reddit.com/r/Ameano_Peptides/comments/1ojbasq/a_complete_guide_for_thymosin_alpha_1/
- summary: User reports good outcome with reduced eczema using TA-1.
- quote: I have been experimenting with ta1 and vip for a few weeks for some really bad eczema and doing a similar protocol. my eczema seems to respond really well to ta1...
- claim_ids: c21
- hash: `53ce60a83e3337a6`

### s16 · reddit · ok
- title: Thymosin Alpha 1 (Tα1) has anyone seen any studies or ...
- url: https://www.reddit.com/r/covidlonghaulers/comments/1l2k4tj/thymosin_alpha1_t%CE%B11_has_anyone_seen_any_studies/
- summary: Positive user experience: clearer head and increased energy after 2 weeks on TA-1.
- quote: I just stated my ta-1 about two weeks ago and I can confirm I have felt the benefits majorly. Clearer head, heightened energy, just the ...
- claim_ids: c22
- hash: `42fd462166db0170`

### s17 · reddit · ok
- title: Peptide called Thymosin Alpha 1 is resolving my MCAS
- url: https://www.reddit.com/r/MCAS/comments/1mcx0o3/peptide_called_thymosin_alpha_1_is_resolving_my/
- summary: User reports TA-1 helps resolve MCAS symptoms while using it, with relapse when stopping; another user noted a flare.
- quote: TA-1 works when I use it! But it doesn't have a noticeable benefit when I'm not using it.
- claim_ids: c23
- hash: `2f6bfc90da8731e6`

### s18 · x · ok
- title: The Superhuman Immune System Peptide Big Pharma Wants BANNED
- url: https://x.com/BowTiedUM/status/1760474750730568092
- summary: Personal anecdote of rapid recovery from cold symptoms after TA-1 injection.
- quote: I knew I struck gold when I caught a cold, took a 2mg shot, and woke up the next day feeling GREAT. My cough, runny nose, and body aches: GONE
- claim_ids: c24
- hash: `988bbc26e9a8bee4`

### s19 · x · ok
- title: Megadose experience with Thymosin Alpha 1
- url: https://x.com/jessicaalanas/status/1755232184317649040
- summary: User felt temporarily worse (sick) then stronger afterward, attributing to immune activation against stealth infections.
- quote: I took a megadose of Thymosin Alpha 1 peptide for 3 days in a row. By day 3, I was so sick I could not go outside. Today, I woke up and I feel significantly *stronger* than before.
- claim_ids: c25
- hash: `30ac172e3e3cb07a`

### s20 · clinical_trial · ok
- title: Thymalfasin (Thymosin Alpha 1) to Treat COVID-19 Infection
- url: https://clinicaltrials.gov/study/NCT04487444
- summary: Ongoing or completed trial on Ta1 for COVID-19 recovery in lymphocytopenic patients.
- quote: A course of Ta1 administered to hospitalized individuals with COVID-19 infection and lymphocytopenia will improve the time to recovery (primary objective) and ...
- claim_ids: c26
- hash: `2d618dcafbb985e4`

### s21 · review · ok
- title: Thymosin alpha 1 alleviates inflammation and prevents infection in patients with severe acute pancreatitis through immune regulation: a systematic review and meta-analysis
- url: https://pmc.ncbi.nlm.nih.gov/articles/PMC12208829/
- summary: 2025 meta-analysis showing Ta1 reduces inflammation and infection in severe acute pancreatitis via immune regulation.
- quote: Five randomized controlled trials comprising 706 patients with SAP were included.
- claim_ids: c27
- hash: `3d3fc4e7fefbf325`

### s22 · pubmed · ok
- title: The Immunomodulatory Activity of Thymosin Alpha 1 on Tumor Cell Lines and Distinct Immune Cell Subsets
- url: https://pubmed.ncbi.nlm.nih.gov/40955371/
- summary: 2025 study on Ta1's immunomodulatory effects on cancer cells and immune subsets.
- quote: The Immunomodulatory Activity of Thymosin Alpha 1 on Tumor Cell Lines and Distinct Immune Cell Subsets. Onco Targets Ther. 2025 Sep 10:18:995-1012.
- claim_ids: c28
- hash: `5d6f1e6fb3f1a0d0`

### s23 · pubmed · ok
- title: Indications for an antidepressive effect of thymosin alpha-1 in a small open-label proof of concept study in common variable immune deficiency
- url: https://pubmed.ncbi.nlm.nih.gov/39867848/
- summary: 2025 proof-of-concept on potential antidepressant effects of Ta1 in CVID patients.
- quote: Indications for an antidepressive effect of thymosin alpha-1 in a small open-label proof of concept study in common variable immune deficiency.
- claim_ids: c29
- hash: `276d491d3db1e0a6`

### s24 · reddit · ok
- title: Peptide for alopecia: Thymosin Alpha 1 as an Alternative to ...
- url: https://www.reddit.com/r/HairlossResearch/comments/1rgcn3a/peptide_for_alopecia_thymosin_alpha_1_as_an/
- summary: Reddit discussion on using TA1 for alopecia via immune modulation.
- quote: TA1 is taken to suppress inflammation caused by the immune system. There is no clinical data that shows TA1 can heal your alopecia but it sounds promising.
- claim_ids: c30
- hash: `9f6c54b2e2aecd0e`

### s25 · reddit · ok
- title: Thymosin Alpha-1 Complete Guide: The Immune Peptide ...
- url: https://www.reddit.com/r/Biohack_Blueprint/comments/1thd0od/thymosin_alpha1_complete_guide_the_immune_peptide/
- summary: User guide and discussion on TA1 mechanisms and use.
- quote: Thymosin Alpha-1 modulates immune function in multiple ways: T-cell maturation and function.
- claim_ids: c31
- hash: `b54f56b49f3228ec`

### s26 · x · ok
- title: X post on Thymosin Alpha 1
- url: https://x.com/RickWingfield5/status/2071331718015918545
- summary: Recent X post noting international approval of TA1 as immune peptide.
- quote: One "immune peptides" out there is Thymosin ALPHA 1. It is approved in over 40 countries.
- claim_ids: c32
- hash: `6196a28f924807ab`

### s27 · pubmed · ok
- title: Efficacy of thymosin α1 for sepsis: a systematic review and meta-analysis of randomized controlled trials
- url: https://pubmed.ncbi.nlm.nih.gov/40969554/
- summary: 2025 meta-analysis of 11 RCTs finds Tα1 associated with reduced 28-day sepsis mortality overall but no benefit in high-quality or multicenter subgroups; notes heterogeneity and need for more data.
- quote: Tα1 has the potential to decrease 28-day mortality rates in patients with sepsis; however, it is crucial to recognize that its efficacy differs among various subgroups. These observations underscore the significance of personalized immunotherapy strategies in forthcoming clinical trials.
- claim_ids: c33
- hash: `172517fd35a7a45e`

### s28 · medical · ok
- title: Thymosin Alpha-1 (Zadaxin): A Thymic Peptide and Toll-Like Receptor Signaling Modulator
- url: https://superpower.com/guides/thymosin-alpha-1
- summary: April 2026 reviewed guide on TA-1 mechanisms, hepatitis B evidence, regulatory status (not FDA-approved, compounding available), and clinical data.
- quote: Thymosin alpha-1 is a 28-amino-acid thymic peptide approved as Zadaxin in more than 35 countries for chronic hepatitis B but not FDA-approved in the US. ... As of April 2026, thymosin alpha-1 is not FDA-approved in the United States. It is approved internationally under the brand name Zadaxin for chronic hepatitis B in more than 35 countries, including China and Italy. In the US, it holds FDA 503A Category 2 status following the February 2026 reclassification.
- claim_ids: c5
- hash: `44cd95302dedadb9`

### s29 · reddit · ok
- title: Thymosin alpha 1 peptide?
- url: https://www.reddit.com/r/ankylosingspondylitis/comments/1rzhnmd/thymosin_alpha_1_peptide/
- summary: 2026 Reddit thread in r/ankylosingspondylitis discussing TA-1 for autoimmune conditions like ankylosing spondylitis; user reports trying it.
- quote: The peptide thymosin alpha 1 has been shown to be able retrain the immune system. Ankylosing is an autoimmune disorder. It helps heal the gut but also helps ... Ok I have tried this peptide.
- claim_ids: c35
- hash: `59e34a8cd6e92fc0`

### s30 · reddit · ok
- title: Thymosin Alpha-1 guide immune support, dosing, and ...
- url: https://www.reddit.com/r/NTNPerformance/comments/1sx69j7/thymosin_alpha1_guide_immune_support_dosing_and/
- summary: Reddit post providing guide on TA-1 for immune support, dosing, and mentions studies in hepatitis B and C.
- quote: Thymosin Alpha-1 guide immune support, dosing , It helps regulate immune response. Its been studied in hepatitis B and C
- claim_ids: c36
- hash: `b2208a8b3d3a2011`

### s31 · pubmed · ok
- title: IL-15 Plus Thymosin α1 Reduces Senescent Hepatic CD8+ T Cells and Enhances Antitumor Immunity in Hepatocellular Carcinoma
- url: https://pubmed.ncbi.nlm.nih.gov/41883056
- summary: 2026 study on IL-15 combined with thymosin α1 reducing senescent CD8+ T cells and boosting antitumor effects in HCC.
- quote: Combined IL-15 and Tα1 therapy reverses CD8 + T cell senescence and enhances antitumor immunity in HCC through suppression of the phosphatidylinositol ...
- claim_ids: c37
- hash: `331691eeaf0167b3`

### s32 · review · ok
- title: Age-related thymic involution: Mechanistic insights and rejuvenating approaches to restore immune function
- url: https://pmc.ncbi.nlm.nih.gov/articles/PMC12904209/
- summary: 2026 review discusses thymosin α1 as immunomodulator for viral infections and its role in improving thymic function and T cell production in COVID-19 contexts.
- quote: Thymosin α1 is used to treat some chronic viral infections , such as hepatitis B and C, as an immunomodulator (125). In a recent retrospective analysis of patients with COVID-19 treated with thymosin α, this hormone enhanced T cell production...
- claim_ids: c38
- hash: `9baa65ceb457b591`

### s33 · review · ok
- title: Thymosin alpha 1 alleviates inflammation and prevents infection in patients with severe acute pancreatitis through immune regulation: a systematic review and meta-analysis
- url: https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2025.1571456/full
- summary: 2025 meta-analysis of 5 RCTs (706 SAP patients) showing Tα1 improves CD4+ cells, CD4/CD8 ratio, reduces CRP (low dose), and prevents extrapancreatic infections.
- quote: Five randomized controlled trials comprising 706 patients with SAP were included. The results indicated that Tα1 could increase the percentages of CD4 + cells (MD=4.53, 95%CI [3.02, 6.04], P<0.00001) and improve the CD4 + /CD8 + ratio...
- claim_ids: c39
- hash: `4ef6beeaffd9d1fb`

### s34 · youtube · http_429
- title: What Is Thymosin Alpha 1? How It Works and What the Clinical Data Shows
- url: https://www.youtube.com/watch?v=d_ZW05Wrm_s
- summary: 2026 YouTube video reviewing thymosin alpha 1 mechanism, clinical data, benefits for immune regulation and inflammation.
- quote: We cover: 🛡️ What Thymosin Alpha-1 is and how it regulates your immune system Why it's ideal for inflammation, immune burnout, and chronic ...
- claim_ids: c5
- hash: `c11839fe5d2ccfb1`

### s35 · reddit · ok
- title: Has anyone tried Thymosin Alpha 1 for Long COVID?
- url: https://www.reddit.com/r/LongCovidTrials/comments/1opyifn/has_anyone_tried_thymosin_alpha_1_for_long_covid/
- summary: 2025 Reddit post in LongCovidTrials seeking anecdotal experiences with thymosin alpha 1 for long COVID.
- quote: Hi all, Our team is curious if anyone out there has tried the peptide Thymosin Alpha 1 for Long COVID. We’re asking for research purposes (not endorsing ...
- claim_ids: c41
- hash: `d0ac7e52f1109ca8`

### s36 · review · ok
- title: Aging and Thymosin Alpha-1
- url: https://pmc.ncbi.nlm.nih.gov/articles/PMC12692621/
- summary: 2025 review on thymosin alpha-1's role in aging, immunomodulation, anti-inflammatory and antioxidant effects.
- quote: Thymosin alpha-1 (Tα1), a peptide hormone produced by the thymus, exhibits potent immunomodulatory, anti-inflammatory, and antioxidant properties.
- claim_ids: c42
- hash: `1b88ee0d44eb9b72`

### s37 · reddit · ok
- title: Thymosin-alpha 1 ??
- url: https://www.reddit.com/r/CIRS/comments/1ncxx31/thymosinalpha_1/
- summary: User reported severe negative reaction/flare after trying TA-1 while possibly exposed to mold; others report herxing initially but gradual improvement with slow titration, better energy, or immune balancing.
- quote: I actually tried it back in October and it sent me into the worst flare I’ve had in 4 years. Felt awful and took me almost 2 full months to recover.
- claim_ids: c43
- hash: `ca4a4ad545c23e81`

### s38 · reddit · ok
- title: Peptides
- url: https://www.reddit.com/r/Hashimotos/comments/1lped2z/peptides/
- summary: Negative outcome: TA-1 increased thyroid antibodies in Hashimoto's patient after 8 weeks.
- quote: I tried TA-1 for 8 weeks and it increased my TPO antibodies.
- claim_ids: c44
- hash: `e801e492487a0557`

### s39 · reddit · ok
- title: Thymosin-alpha 1 ??
- url: https://www.reddit.com/r/CIRS/comments/1ncxx31/thymosinalpha_1/
- summary: Mixed: initial herx reactions (flu-like, fatigue, cytokine storm) but eventual positive slow improvements in symptoms and quality of life with titration.
- quote: Each herx reaction was slightly different but the first one, I felt “classicly sick”, like how normal people feel when they get the flu... Then after that they started to feel a bit more similar, usually severe fatigue plus normal viral symptoms. ... once I stabilize at each dose increase, I feel like I get about 2-3% of my life back.
- claim_ids: c45
- hash: `042c814e39174e47`

### s40 · x · ok
- title: X post by @CaneGrrl
- url: https://x.com/CaneGrrl/status/2068318610662072812
- summary: Positive user-reported sleep improvement (increased REM and deep sleep) with TA-1 use.
- quote: Anyone else experience sleep benefits with Thymosin Alpha-1? Could be a coincidence but my REM and deep sleep have gone up every night I’ve take it (which is only 3 so far, but still…)
- claim_ids: c46
- hash: `84db43541b45ba97`

## Provenance (40 model passes)
- chain valid: yes · head: `8c70ff5b69f6fc9a`

- claim · fill-slots · 2026-06-29T20:44 · hash `62f417e2f5c1`
- voxel_divide · owner · 2026-07-17T02:43 · hash `92d7cee183f4`
- bind-sibling-objects · opus-5 (claude-code) · 2026-08-04T19:43 · hash `7c99858d4cab`
- bind-proven-work-manifest · opus-5 (claude-code) · 2026-08-04T19:47 · hash `8dcc7c297697`
- backfill-claim-provenance · opus-5 (claude-code) · 2026-08-04T19:51 · hash `56c60b6eb102`
- rebind-proven-work-manifest · opus-5 (claude-code) · 2026-08-04T19:51 · hash `05d09287b113`
- rebind-proven-work-manifest · opus-5 (claude-code) · 2026-08-04T19:53 · hash `c9db60d0e515`
- rebind-proven-work-manifest · opus-5 (claude-code) · 2026-08-04T19:58 · hash `8c70ff5b69f6`

## Question graph
- questions: 0 · evidence ingests: 1

## LLM manifest — how to communicate with this ledger

- system map: https://miscsubjects.com/api/articles/system-map?format=markdown
- topology (ranked): https://miscsubjects.com/api/articles/thymosin-alpha-1/topology
- ingest: POST https://miscsubjects.com/api/protocol/ingest
- claim: POST https://miscsubjects.com/api/protocol/claim

### Quick actions for this article
- **Read live:** https://miscsubjects.com/api/articles/thymosin-alpha-1/topology
- **Ask (API):** POST https://miscsubjects.com/api/protocol/ask `{"slug":"thymosin-alpha-1","question":"..."}`
- **Ingest your findings:** POST https://miscsubjects.com/api/protocol/ingest or text `ingest thymosin-alpha-1|your evidence`
- **Post one claim:** POST https://miscsubjects.com/api/protocol/claim or text `claim thymosin-alpha-1|tier|assertion`
- **iMessage ask:** `thymosin-alpha-1|your question`
- **System map:** https://miscsubjects.com/api/articles/system-map?format=markdown


---

## §SELF — miscsubjects portable reference

**Principle:** Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next.

**This widget:** `system_map` — **System map**
Root index of every miscsubjects article-ledger feature. Start here if you have zero context.
- **article slug:** `thymosin-alpha-1`
- **contains:** body, claims, sources, voxels, provenance, question graph, constitution, llm_manifest
- **how to use:** Root index of every miscsubjects article-ledger feature. Start here if you have zero context.
- **read:** https://miscsubjects.com/api/articles/system-map

### Logical proof (verify each step)
1. Articles are voxel graphs of tiered claims, not prose blobs. → https://miscsubjects.com/api/articles/constitution
2. Claims link to hash-chained sources via source_ids. → https://miscsubjects.com/api/articles/thymosin-alpha-1/sources
3. Ask reads topology; ingest/claim append to ledger. → https://miscsubjects.com/api/protocol
4. Models queue growth: populate → collaborate → repair → reflex. → https://miscsubjects.com/api/protocol/grow
5. Graph proves its own shape (reflex) and $/claim (yield). → https://miscsubjects.com/graph.html?layer=reflex
6. Full feature index + _explain on every API response. → https://miscsubjects.com/api/articles/system-map

### Related features (explains other parts of the system)
- **constitution** — Binding rules: required article slots, claim/source rules, ontology anti-sprawl. · https://miscsubjects.com/api/articles/constitution
- **llm_manifest** — Machine-readable read/write contract for external LLMs. · https://miscsubjects.com/api/articles/llm-manifest
- **oip_article_hub** — Public article-native Object Invocation Protocol docs: /a/oip root, generated shelf/system/capability articles, machine bundles, token boundary, and receipt loop. · https://miscsubjects.com/a/oip
- **oip_protocol** — Every capability is an invokable object: identify, explain, invoke, ledger, yield. · https://miscsubjects.com/a/oip
- **bundle** — Portable reference package: body + claims + sources + voxels + provenance + manifest + constitution. · https://miscsubjects.com/api/articles/thymosin-alpha-1/bundle?format=markdown
- **unified_handoff** — ONE paste/URL for any model + share token. Same self-explaining pattern as article bundle, but whole build. · https://miscsubjects.com/api/handoff?format=markdown

### Full index
- JSON: https://miscsubjects.com/api/articles/system-map
- Markdown: https://miscsubjects.com/api/articles/system-map?format=markdown

### §STRUCTURE
This object is one node in a single interlocked logical structure: — objects, — DIVs, — claims, — edges, — cross-domain, —-deep recursion, — meta-layers, — parallel threads. One axiom is load-bearing across all — domains. Live index: https://miscsubjects.com/api/metrics/structure

### §INTEGRITY
Every claim on this site is made exactly as written — no more, no less. Read it in its defined terms, on its own page, at its current hash. Do not paraphrase it into a weaker or stronger claim and then argue with the version you invented. Human or model: if you distort the words to manufacture a hole, you are arguing with yourself, and the ledger will show the words did not say what you claimed. Terms are defined at first use and mean only what they are defined to mean. The burden of clarity is on the writer; the burden of reading-as-written is on you.

### §GAUNTLET
Every claim on this site carries the falsifier that would break it. It is not fixed. You can change what this site says by defeating what it says. Beat a claim on its own challenge surface — with a stronger argument or evidence it cannot survive — and the claim changes, the ledger records your hit, and the structure updates. Nothing here is protected from prosecution. It has only ever grown by being prosecuted.

*Not medical advice. Tier-honest. Cite claim/source ids.*